READINGTON, N.J. (NBC) – The drugmaker Merck says its experimental COVID-19 pill is not as effective as previously reported.
New data from its study shows the pill can reduce hospitalizations and deaths by 30% down from 50% reported last month.
U.S. health officials are also raising questions about the safety of the pill during pregnancy.
The Food and Drug Administration will hold a public meeting next week where experts will debate the drug’s benefits and risks.
If the FDA gives the drug its approval, it will be the first covid-19 pill for U.S. patients who have the virus.